Sunshine Biopharma, Inc. (SBFM)
| Market Cap | 5.18M -5.7% |
| Revenue (ttm) | 36.31M +4.1% |
| Net Income | -5.98M |
| EPS | -1.44 |
| Shares Out | 4.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,279 |
| Open | 1.030 |
| Previous Close | 1.030 |
| Day's Range | 1.010 - 1.064 |
| 52-Week Range | 0.950 - 2.430 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+563.51%) |
| Earnings Date | May 13, 2026 |
About SBFM
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-parti... [Read more]
Financial Performance
In 2025, Sunshine Biopharma's revenue was $36.31 million, an increase of 4.11% compared to the previous year's $34.87 million. Losses were -$5.98 million, 16.4% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for SBFM stock is "Strong Buy" and the 12-month stock price target is $7.0.
News
Sunshine Biopharma reports FY25 EPS ($1.44) vs. ($7.32) last year
Reports revenue $36.3M vs. $34.9M last year. “We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future,” said Dr. Steve Slilaty,…
Sunshine Biopharma expects to reduce expenses by $2M-$3M in 2026
The company said, “In January 2026, Sunshine Biopharma (SBFM) implemented cost-reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company’s focus on achievi...
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medi...
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ: SBFM) is quickly establishing which side of that...
Sunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidone
Sunshine Biopharma’s (SBFM) Nora Pharma has received approval from Health Canada for the commercialization of Domperidone, a prescription medication used to relieve nausea and vomiting and to enhance ...
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solut...
Sunshine Biopharma announces commercial launch of doxycycline in Canada
Sunshine Biopharma (SBFM) announced the commercial launch of generic Doxycycline in Canada. This strategic move strengthens the Company’s footprint in the Canadian growing antibiotic sector. Doxycycli...
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
FORT LAUDERDALE, FL / ACCESS Newswire / October 20, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solut...
Sunshine Biopharma’s Nora Pharma launches pravastatin
Sunshine Biopharma’s (SBFM) Nora Pharma has launched Pravastatin, a generic prescription drug in the therapeutic class of Lipid Metabolism Regulators. Pravastatin is a generic version of Pravachol. Pr...
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
FORT LAUDERDALE, FL / ACCESS Newswire / October 16, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety o...
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma (NASDAQ: SBFM) is quietly engineering a flywheel model for biotech. Not a flashy one that spins fast and burns energy and...
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma (NASDAQ: SBFM) is the kind of company that keeps the market honest. On paper, it's small, barely a rounding error next to...
Sunshine Biopharma allocates $5M for investment in bitcoin
Sunshine Biopharma (SBFM) announced its Board of Directors has formally approved a strategic investment of $5M in Bitcoin (BTC-USD) as a strategic reserve asset. This move aligns with Sunshine Biophar...
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines in a v...
Sunshine Biopharma, University of Arizona develop series of protease inhibitors
Sunshine Biopharma (SBFM) has developed a new series of orally active, non-covalent protease inhibitors with dose-dependent antiviral activity in mice infected with SARS Coronavirus. This work was car...
Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections
FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of...
Sunshine Biopharma’s Nora Pharma launches NIOPEG
Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched NIOPEG, the company’s first Biosimilar drug on the market. NIOPEG is a Biosimilar comparable to...
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market
FORT LAUDERDALE, FL / ACCESS Newswire / July 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of th...
Sunshine Biopharma launches generic gabapentin for neuropathic pain
Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Gabapentin, a new generic prescription drug in the therapeutic class of anticonvulsants. G...
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
FORT LAUDERDALE, FL / ACCESS Newswire / June 11, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
FORT LAUDERDALE, FL / ACCESS Newswire / May 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of th...
Sunshine Biopharma launches generic Lurasidone for schizophrenia
Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched Lurasidone, a new generic prescription drug in the therapeutic class of antipsychotics. Lurasid...
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
FORT LAUDERDALE, F / ACCESS Newswire / May 6, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ther...
Sunshine Biopharma launches Everolimus in Canada
Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched Everolimus in the Canadian generic prescription drugs market. Everolimus is a generic equivalen...
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic area...